News brief­ing: Mer­ck buys in­to A2's T cell ther­a­py plat­form; Small Soli­genix re­ports PhI­II fail in head and neck can­cer

Mer­ck is dip­ping its toes in­to a cell ther­a­py part­ner­ship with A2 Bio­ther­a­peu­tics, with an of­fer to co-fund clin­i­cal de­vel­op­ment and al­lo­gene­ic man­u­fac­tur­ing ac­tiv­i­ties through …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER